Roche assumes development of KSQKSQ's USP1 inhibitorUSP1 inhibitor for cancer

13 Jul 2023
firstwordpharma.com
Phase 1License out/inImmunotherapy
Roche and KSQ Therapeutics have entered into a worldwide license and collaboration agreement for the development and commercialisation of KSQ-4279, which is being studied as a treatment for solid tumours, KSQ announced on Thursday. Roche will assume the development of the first-in-class, selective small molecule inhibitor of USP1, a protein regulating DNA damage response (DDR). Financial terms of the deal were not disclosed,
James Sabry, Roche global head of pharma partnering, said that "DDR is a promising and emerging area of research in oncology," adding that KSQ-4279 "is a potential new treatment option for patients with significant unmet medical needs across a range of cancers." KSQ chief executive Qasim Rizvi explained that KSQ-4279 "was discovered through our proprietary CRISPRomics platform," adding that "this agreement enables us to fully focus our attention on advancing our own immunotherapy programmes and to continue leveraging our successful platform to discover novel targets."
Under the agreement, KSQ will receive an upfront payment and will be eligible to receive additional milestone and royalty payments. Roche gains a global license and will be fully responsible for the further development of KSQ-4279 in 2024. KSQ-4279 is currently being studied in a Phase I dose-escalation and expansion trial in patients with advanced solid tumours, as a monotherapy and in combination.
In January, several research-stage DDR programmes uncovered by KSQ's CRISPRomics platform were acquired by Ono Pharmaceutical. In May, KSQ and Takeda expanded a 2021 collaboration to research and validate novel tumour-intrinsic targets.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.